FAST BioMedical Welcomes Dr. Trey Putnam as Vice President of Regulatory Affairs and CMC


Carmel, IN — March 9, 2018 — FAST BioMedical today announced that Dr Trey Putnam has been named as their new Vice President of Regulatory Affairs and CMC. Dr. Putman is an expert in regulatory affairs and manufacturing with over eighteen years of product development experience. He will oversee the development and execution of FAST BioMedical’s regulatory strategy, injectable manufacturing, and quality systems.

Dr. Putnam earned his Regulatory Affairs Certification (United States) in 2007 from the Regulatory Affairs Professional Society (RAPS) and is a routine contributor to the RAPS’ publication Fundamentals of US Regulatory Affairs. Dr. Putnam was previously the General Manager of Cardinal Health Regulatory Sciences where he led Cardinal Health’s scientific and regulatory consulting business unit which included more than 200+ regulatory affairs associates. As part of Cardinal Health Regulatory Sciences, Dr. Putnam played an integral role in the development and approval of dozens of pharmaceutical, biologic and medical device products. Dr. Putnam earned a PhD and MA in Organic Chemistry from Washington University in St. Louis where his research focused on drug discovery of therapeutic oligonucleotides.

“Being able to attract talent the caliber of Dr. Putnam is very gratifying.” Said Joe Muldoon, CEO of FAST BioMedical.  “It is a complement to the team he is joining, and further validation of FAST’s potential.  I’m confident Trey will be an immediate and significant contributor.”

Dr. Putnam’s extensive experience in regulatory affairs, quality and product development will be critical as FAST BioMedical moves it’s technology forward.

About FAST BioMedical

FAST BioMedical is a private, clinical-stage medical technology company in Carmel, Indiana.  The company’s globally patented first-in-class technology directly measures blood volume and kidney function in a clinically actionable way.  This has the potential for profound impact on care of heart failure, cardio-renal, major surgery, sepsis, critical care, and kidney disease patients.   The company has been financially supported by the NIH, Elevate Ventures, the Indiana 21st Century Fund, Rose-Hulman Ventures, BioCrossroads, Indiana University Medical Group, The Purdue Foundry Fund, Ellipsis Ventures, VisionTech Partners, and private family office investors. The FDA has determined the company’s technology met the requirements for an Expedited Review.  These products are investigational and not yet approved for human use.

For more information, please visit